# Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.

> **NCT02919059** · PHASE4 · UNKNOWN · sponsor: **IInstituto Gallego de Medicina Vascular** · enrollment: 159 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dapagliflozin 10 mg
- **DRUG:** Glimepiride 4 mg

## Key facts

- **NCT ID:** NCT02919059
- **Lead sponsor:** IInstituto Gallego de Medicina Vascular
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12-13
- **Primary completion:** 2018-12
- **Final completion:** 2019-08
- **Target enrollment:** 159 (ESTIMATED)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02919059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02919059, "Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02919059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*